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discrete appearance of the
involved mediastinal lymph
nodes and limited extent of
mediastinal lymph node
involvement at diagnosis
showed favorable survival
outcomes but relatively high
local recurrence rates after
definitive chemoradiation
therapy. These patients could
be candidates for multi-
modality approach including
surgical resection after in-
duction therapy.discrete or infiltrative according to the criteria proposed by the American College
of Chest Physicians. In addition, the extent of MLN involvement (MLNI) was clas-
sified as limited (close to the primary tumor) or extensive (including upper MLNI
in the case of tumors in the lower lobes and vice versa).
Results: A total of 148 patients with cIIIA-N2 NSCLC was treated by CRT. The
patient characteristics were as follows: males: 118; females: 30; median age:
62 years; appearance of the involved MLNs: 85 discrete, 63 infiltrative; extent of
MLNI: 82 limited, 66 extensive; histology: 36 squamous, 112 nonsquamous. The
median progression-free survival (PFS) and median overall survival (OS) in the
entire subject population were 9.9 and 34.7 months, respectively. A discrete appear-
ance of the involved MLNs and a limited extent of MLNI contributed significantly
to a better PFS and OS. The percentages of cases with relapses within the irradiated
field classified according to the characteristics of the MLNs were as follows;
appearance of the MLNs (24.6% discrete, 18.9% infiltrative); extent of MLNI
(25.9 limited, 17.9% extensive).
Conclusions: Those with a discrete appearance of the involved MLNs and a limited
extent of MLNI at diagnosis could show relatively more favorable outcomes and
could be candidates for multimodality therapy.  2016 The Authors. Published by
Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Approximately 30% of patients with non-small cell lung
cancer (NSCLC) are diagnosed as having stage III disease
at the point of initial treatment (1). Constant efforts have
been directed at finding better loco-regional and systemic
treatments for patients with stage III NSCLC (2). Albain
et al (3) conducted an important phase 3 trial (INT-0139)
comparing chemoradiation therapy (CRT) and CRT fol-
lowed by surgery in patients with clinical stage IIIA
NSCLC with N2 nodal involvement (cIIIA-N2). Although
the trial did not yield positive results in respect to the
primary endpoint, CRT followed by surgery appeared to
confer possible benefit in patients who were eligible for
lobectomy. Radiation Therapy Oncology Group study
0617 evaluated both loco-regional and systemic re-
inforcements in a phase 3 trial with a factorial design: a
higher dose (72 Gy) versus a standard dose (60 Gy) of
definitive thoracic radiation therapy (TRT) plus systemic
treatment using cetuximab versus treatment without
cetuximab. However, Bradley et al (4) reported that the
primary endpoint was not achieved in either treatment
arm. Therefore, the standard treatment for patients with
cIIIA-N2 NSCLC remains definitive CRT with 60 Gy of
TRT.
These findings suggest that a rigorous research to select
potential candidates for intensive local therapy is needed.
We investigated the influence of the appearance of the
involved MLNs and the extent of mediastinal lymph node
involvement at diagnosis on the frequency of local relapses
and the outcomes in patients with cIIIA-N2 NSCLC treated
by definitive CRT.Methods and Materials
Patients
Patients with cIIIA-N2 NSCLC who received definitive
thoracic radiation therapy (TRT) with platinum-based
chemotherapy regimens between 1997 and 2010 were
eligible for the analysis. Patients who had received TRT
alone, TRT at a total radiation dose of under 50 Gy,
chemotherapy alone or treatment based on clinical trials
were excluded. Data on the pretreatment patient character-
istics, including the age, sex, Eastern Cooperative Oncology
Group performance status (ECOG PS), and smoking his-
tory, and the tumor characteristics including the histology
and tumor-node-metastasis (TNM) stage according to
Union for International Cancer Control, seventh edition,
were retrieved from the medical records (5). The treatment
characteristics, including the radiation dose and the timing
of the TRT (concurrent or sequential) and the chemotherapy
regimens employed, were also evaluated. This study was
conducted in accordance with the principles laid down in
the amended Declaration of Helsinki. The study protocol
was approved by the institutional review boards of the
National Cancer Center Hospital (number: 2013-261).Treatment
Patients usually received concurrent TRT with platinum-
based combination chemotherapy as the standard treatment.
TRT was delivered with megavoltage equipment (6 MV)
using anterior/posterior opposed fields, at 40 Gy delivered
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mary tumor, the metastatic lymph nodes, and the regional
nodes (elective nodal irradiation). A booster dose of 20 to
26 Gy in 10 to 13 fractions was given to the primary tumor
and the metastatic lymph nodes to a total dose of 60 to
66 Gy using bilateral oblique fields. Computed tomography
(CT)-based treatment planning was used in the majority of
the patients.Staging
The T, N, and M staging were performed based on the CT
and 18F-labeled fluorodeoxyglucose positron emission to-
mography (PET) findings. The staging and diagnosis of
lymph node involvement (N status) were initially con-
ducted by experienced radiologists and independently
reviewed by another investigator. All metastatic lymph
nodes were classified according to the International Asso-
ciation for the Study of Lung Cancer node map (6). The
appearance of the mediastinal lymph nodes (MLNs) was
classified into MLNs with discrete appearance or with
extensive infiltration (abbreviated to “infiltrative” in this
study) according to the criteria proposed by the American
College of Chest Physicians (ACCP) mainly for surgical
decision making in the multidisciplinary team discussion
(7). The extent of MLN involvement (MLNI) was classified
as N2a-1 (limited) or N2a-2 and N2b (extensive) according
to the Japanese nodal classification proposed by the Japan
Lung Cancer Society (JLCS), which is usually applied to
surgically resected lung cancer (Table 1) (8, 9).
N2 status was diagnosed based on pathology and im-
aging studies. The pathology diagnoses were based on
examination of mediastinoscopic and surgical or trans-
bronchial needle biopsy specimens. Infiltrative MLNs wereTable 1 Definition of the extent of MLNI* according to
JLCSy
Right Left
Upper Middle Lower Upper
Upper
(lingula) Lower
N2a-1
(limited
MLNI)
2R 2R 7 4L 4L 7
4R 4R 8 5 5 8
7 9 6 6 9
7
N2a-2 and N2b
(Extensive
MLNI)
7 3a 2R 7 2L 4L
3a 3p 4R 2L 3a 5
3p 8 3a 3a 3p 6
8 9 3p 3p 8 2L
9 8 9 3a
9 3p
Abbreviations: JLCS Z Japan Lung Cancer Society;
MLNI Z mediastinal lymph node involvement.
* Each number refers to the station of lymph nodes in the Interna-
tional Association of the Study of Lung Cancer staging atlas (7).
y Modified from the Japanese nodal classification for resected lung
cancer (10).diagnosed as N2 based on CT findings, regardless of PET
findings. Discrete MLNs were diagnosed as N2 if they had
a short diameter of 1 cm on CT, regardless of the PET
findings. Routine screening using PET-CT was started in
2005 at our institution.
Statistical analysis
Clinical outcomes were analyzed using the Kaplan-Meier
method, and the log-rank test was used to compare out-
comes. Cox proportional hazard model was used for
multivariate analyses performed to evaluate the effect of the
appearance of the involved MLNs and extent of MLNI on
the progression-free survival (PFS) and overall survival
(OS) with adjustment for known and important co-factors
such as the age, sex, body weight loss (<5% or 5%),
ECOG PS (0 or 1), smoking history, histology, method used
to diagnose N2, timing of the TRT, and the initial date of
treatment. The overall response rate (ORR) was measured
in patients who had measurable lesions according to
Response Evaluation Criteria In Solid Tumors version 1.1
criteria (10). STATA version 13 software (StataCorp, Col-
lege Station, TX) for Windows (Microsoft, Redmond, WA)
was used for statistical analyses.
Results
Patient characteristics
Between 1997 and 2010, unresectable cIIIA-N2 NSCLC
was diagnosed in a total of 188 patients at the National
Cancer Center Hospital, Japan. Of these, we excluded 40
patients and included the remaining 148 patients as eligible
for this analysis. Forty of the 188 patients were excluded
because they were treated by radiation therapy alone (nZ7),
treated by radiation therapy at a total radiation dose lower
than 50 Gy (nZ2), or treated by chemotherapy alone
(nZ1), their chemotherapy component was based on non-
platinum chemotherapy regimen (nZ1), nonavailability of
clinical data (nZ4), or they were included as subjects in
other clinical trials (nZ25).
Characteristics of the 148 patients were as follows:
median age 62 (range: 33-77) years; male-to-female ratio
118:30; body weight loss (5% in males, <5% in females)
17:131; ECOG PS (0/1) 61/87; and tumor histology (non-
squamous/squamous) 112/36. According to the pretreat-
ment evaluation, 85 patients (57%) had a “discrete”
appearance of the MLNs, 82 patients (55%) had “limited”
MLNI. N2 diagnoses were based on imaging studies (CT
and PET-CT) in 117 cases (79%) and on pathology exam-
inations in 31 cases (21%) (Table 2).
Treatment summary
Of the 148 patients, 133 (90%) received concurrent TRT
and the remaining 15 (10%) received sequential TRTwith a
Table 2 Patient characteristics
Characteristic
No. of
patients
(NZ148)
% or
range
Median age (y) 62 33-77
Sex
Male 118 80
Female 30 20
Body weight loss
5% 17 11
<5% 131 89
Performance status
0 61 41
1 87 59
Smoking history (median pack-years) 43 0-156
Appearance of the MLNs
Discrete 85 57
Infiltrative 63 43
Extent of MLNI
Limited 82 55
Extensive 66 45
Tumor histology
Non-squamous 112 76
Squamous 36 24
N2 diagnosis
Imaging study 117 79
Pathological 31 21
Radiation therapy, timing
Concurrent 133 90
Sequential 15 10
Median radiation therapy dose 60 52-66
Chemotherapy
CDDP þ VNR 95 64
Nedaplatin þ PTX 16 11
CBDCA þ PTX 10 7
MVP 9 6
Others 18 12
Treatment begun
Before 2005 85 57
After 2005 63 43
Abbreviations: CBDCA Z carboplatin; CDDP Z cisplatin;
MLNI Z mediastinal lymph node involvement; MVP Z mitomycin
C þ vindesine þ cisplatin; PTX Z paclitaxel; VNR Z vinorelbine.
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combined chemotherapy regimens were as follows;
cisplatin plus vinorelbine, 95 patients; nedaplatin plus
paclitaxel, 16 patients; carboplatin plus paclitaxel, 10
patients; mitomycin plus vindesine plus cisplatin, 9
patients; others, 18 patients.
Patterns of the initial relapses
Of the 148 patients included in this study, 112 (76%)
developed disease recurrences. The initial site of relapse
was local alone in 21.4% of patients, mixed in 17.9% of
patients, and distant alone in 60.7% of patients, including
17% with brain metastasis as the sole site of recurrence.
The frequency of local relapses was higher in patients withlimited MLNI (25.9%), discrete appearance of the MLNs
(24.6%) and a squamous histology (52%). (Table 3)
In the subgroup with pathologically proven N2 disease,
the frequency of local and mixed relapses was higher in
patients with limited MLNI than in those with extensive
MLNI (41.7% compared to 25.0% in patients with exten-
sive MLNI), but similar between patients with discrete and
infiltrative MLNs (35.3% compared to 33.3% in patients
with infiltrative MLNs).
Efficacy
At the point of data cutoff, the median follow-up time was
50.9 months. The percentage of ORR (95% confidence
interval [CI]), median PFS time (months) and median OS
time (months) in the entire study population were: ORR
66.2% (95% CI: 58.5-73.9), median PFS 9.9 months (95%
CI: 9.0-12.3), median OS 34.7 months (95% CI: 28.8-41.1),
and 5-year OS rate 34.0 (95% CI: 25.1-43.1) (Fig. 1).
In the univariate analyses, the median PFS was signifi-
cantly better in patients with discrete MLNs and limited
MLNI. The hazard ratio (HR) for PFS and 5-year PFS rates
in patients with discrete MLNs were 0.70 (95% CI: 0.49-
1.01) and 22.5% (95% CI: 13.7-32.6), respectively. The
same survival parameters in patients with limited MLNI
were 0.59 (95% CI: 0.41-0.85) and 24.4% (95% CI: 15.3-
34.7), respectively. The same patient population also
showed a better HR for OS and 5-year OS rate, as follows;
0.68 (95% CI: 0.44-1.06) and 37.9% (95% CI: 25.3-50.4),
respectively and 0.55 (95% CI: 0.35-0.85) and 44.1% (95%
CI: 30.7-56.7), respectively, in patients with discrete MLNs
and limited MLNI (Fig. 2).
In an exploratory analysis in the subgroup with a path-
ological N2 (31 patients), patients with limited MLNI
showed a better median PFS (15.0 months vs 7.6 months;
HR: 0.43 [95% CI: 0.19-0.99]) and median OS
(46.9 months vs 22.3 months; HR: 0.54 [95% CI: 0.21-
1.38]) compared to those with extensive MLNI.
Based on the Cox proportional hazard model analysis
with adjustment for known and important co-factors, the
adjusted HR for the PFS and OS were as follows: PFS: 0.63
(95% CI: 0.41-0.96) and 0.53 (0.36-0.78), respectively, and
OS: 0.65 (95% CI: 0.39-1.09) and 0.56 (0.35-0.88),
respectively, in patients with discrete MLNs and limited
MLNI. It is also noteworthy that patients who received
CRT after the start of routine PET-CT scanning had at our
institution showed better PFS and OS. (Table 4)
Discussion
To the best of our knowledge, this is the first and most
detailed analysis of the efficacy of definitive CRT in
NSCLC patients with cIIIA-N2 according to the classifi-
cation of the appearance of the involved mediastinal lymph
nodes and extent of mediastinal lymph node involvement
proposed by the ACCP and JLCS guidelines. Although
Table 3 Sites of first relapse
Local (%) Mixed (%)
Distant (%)
Total (%) Brain only (%)
All patients with relapse (NZ112) 21.4 17.9 60.7 17.0
Appearance of the MLNs
Discrete (nZ57) 24.6 21.1 54.3 7.0
Infiltrative (nZ53) 18.9 15.1 66.0 26.4
Extent of MLNI
Limited (nZ54) 25.9 16.7 57.4 16.7
Extensive (nZ56) 17.9 19.6 62.5 17.9
Histology
Squamous (nZ25) 52.0 16.0 32.0 4.0
Non-squamous (nZ87) 12.6 18.4 69.0 20.7
Abbreviation: MLNI Z mediastinal lymph node involvement.
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rate, more favorable outcomes were obtained in cIIIA-N2
patients with discrete MLNs and limited MLNI.1.
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Fig. 1. Survival in all patients with cIIIA-N2 treated by
CRT. In the overall study population (nZ148), the median
PFS was 9.9 months (95% CI: 9.0-12.3), the median OS
was 34.7 months (95% CI 28.8-41.1), and 5-year OS
rate 34.0 (95% CI; 25.1-43.1). Abbreviations: CRT Z
chemoradiation therapy; OS Z overall survival; PFS Z
progression-free survival.Although few reports have discussed the efficacy of CRT
separately for cIIIA-N2 NSCLC, we analyzed the efficacy
and pattern of relapses in this population of patients who
tend to be candidates for multimodality therapy, including
induction CRT followed by surgery. Patients with cIIIA-N2
NSCLC have been reported to show substantially better
median OS (34.7 months) compared to the outcomes of
standard CRT in trials including the entire stage III popu-
lation (11, 12). Because of the heterogeneity of the disease
anatomy and biology, we need to obtain more information to
offer more appropriate local and systemic treatment for
patients with stage III NSCLC. The updated guideline from
ACCP recommends consideration of both definitive CRT
and induction therapy followed by surgery based on
assessment by a multidisciplinary team for patients with
cIIIA-N2 NSCLC with discrete MLNs (2). In this study, we
attempted to define subgroups of patients based on the
appearance of the involved MLNs and the extent of MLNI,
and found that a 5-year PFS rate of more than 20% and
5-year OS rate of approximately 40% were achieved in pa-
tients with discrete MLNs and limited MLNI after definitive
CRT. These pre-treatment patients’ characteristics could be
important factors to consider multimodality therapies.
It has been reported infiltrative appearance (extrac-
apsular invasion) of metastatic lymph nodes is a poor
prognostic factor in surgically treated patients in various
cancers, including lung cancer (13-19). Several reports
suggested that the copy number of aberrations of the
epidermal growth factor receptor gene, expression of alpha
smooth muscle actin, and serine protease inhibitor
(SERPINE1) are correlated with extracapsular invasion in
patients with oral squamous cell carcinoma (18, 19). Con-
cerning the influence of the extent of involvement of the
MLNs, an abundance of articles reported poorer outcomes
in the subgroup of patients with extensive MLNI among
patients with completely resected clinical and pathological
N2 NSCLC (8, 20-23). Our results could be the first to
identify a similar impact of the appearance of the MLNs
and extent of MLNI on the efficacy of CRT and the relapse
pattern after definitive CRT in patients with cIIIA-N2
NSCLC.
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Fig. 2. Survival according to characteristics of the MLNs in the patients with cIIIA-N2 treated by CRT. (A) PFS according
to the appearance of the MLNs. (B) OS according to the appearance of the MLNs. (C) PFS according to the extent of MLNI.
(D) OS according to the extent of MLNI. Abbreviations: CRT Z chemoradiation therapy; MLNI Z infiltrative mediastinal
lymph nodes; OS Z overall survival; PFS Z progression-free survival.
Horinouchi et al. International Journal of Radiation Oncology  Biology  Physics160Concerning local control patients with stage III NSCLC,
higher-dose TRT has failed to exert any clinically mean-
ingful impact on the efficacy or toxicity. (4, 24) In addition
to better chemotherapy regimens or targeted therapies (eg,
tyrosine kinase inhibitors for patients with epidermal
growth factor receptor mutations) for systemic control,
better strategies for selection and treatment of the hetero-
geneous population of patients with stage III NSCLC are
warranted (25). We thoroughly investigated the effect of the
extent of MLNI and appearance of the involved MLNs and
found that even those patients with discrete MLNs and
limited MLNI experienced frequent local relapses within
the radiation field (24.6% in patients with discrete MLNs
and 25.9% in patients with limited MLNI). Although
several phase 3 trials evaluating induction CRT followed by
surgery showed negative results in terms of the endpoint in
the pre-PET/CT era and when the trial patients included the
entire stage III population, further clinical trials based
on contemporary pre-treatment diagnosis (eg, PET-CT,endobronchial ultrasound-guided biopsy) and advanced
surgical management could yield different results (3,26-28).
Our study had several limitations. First, there was an
inevitable bias because of the retrospective nature of the
study. However, we analyzed consecutive patients in a
single institution, which resulted in relatively uniform
methods of diagnosis, treatment, and follow-up. Second,
the proportion of patients who had pathological N2 was
relatively low in comparison with trials of induction
therapy followed by surgery, which may affect the sur-
vival analyses. To confirm the results with those in the
overall population, we conducted a subgroup analysis in
patients with pathological N2 and obtained similar trends
of local relapses and survival. Third, the follow-up period
was not strictly the same in all patients, which could have
resulted in some imbalance. Despite the imbalance, all the
patients were regularly followed-up at every 1 to 2 months
at the outpatient division, and were worked up by radi-
ography, CT, magnetic resonance imaging, and PET-CT
Table 4 Multivariate analyses to identify factors contributing to the PFS and OS
PFS OS
HR 95% CI P value HR 95% CI P value
Age (y)
<62 1 1
62 1.17 0.80-1.71 0.428 1.26 0.80-1.98 0.322
Sex
Male 1 1
Female 0.72 0.39-1.31 0.278 0.73 0.34-1.59 0.426
Body weight loss
<5% 1 1
5% 0.86 0.47-1.57 0.624 0.90 0.45-1.82 0.779
PS
0 1 1
1 0.88 0.58-1.33 0.544 0.86 0.52-1.42 0.553
Smoking history (pack-year)
10 1 1
<10 0.92 0.51-1.66 0.786 0.91 0.41-1.99 0.806
Appearance of MLNs
Infiltrative 1 1
Discrete 0.63 0.41-0.96 0.033 0.65 0.39-1.09 0.106
Extent of MLNI
Extensive 1 1
Limited 0.53 0.36-0.78 0.001 0.56 0.35-0.88 0.013
Histology
Squamous 1 1
Non-squamous 1.61 0.99-2.62 0.056 0.78 0.46-1.34 0.371
N2 diagnosis
Imaging study 1 1
Pathological 0.95 0.58-1.54 0.829 0.93 0.53-1.61 0.788
Radiation therapy, timing
Concurrent 1 NE NE NE
Sequential 1.66 0.83-3.34 0.153
Treatment began
Before 2005 1 1
After 2005 0.63 0.42-0.93 0.022 0.48 0.29-0.79 0.004
Abbreviations: MLNI Z mediastinal lymph node involvement; NE Z not evaluable; OS Z overall survival; PFS Z progression-free survival;
PS Z performance status.
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CRT and every 6 months subsequently.
Conclusions
In conclusion, a limited extent of MLNI and discrete
appearance of the MLNs were associated with a better
survival. However, local relapses were still common in
these relatively favorable subgroups of NSCLC patients
with cIIIA-N2 disease. Further clinical trials are war-
ranted to explore better treatment strategies for the right
patients.
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